Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Manso, Luís
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. [electronic resource] - Anticancer research Dec 2015 - 6941-50 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
1791-7530
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--administration & dosage
Breast Neoplasms--drug therapy
Cross-Sectional Studies
Female
Humans
Neoplasm Metastasis
Paclitaxel--administration & dosage
Quality of Life
Receptor, ErbB-2--metabolism
Triple Negative Breast Neoplasms--drug therapy
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. [electronic resource] - Anticancer research Dec 2015 - 6941-50 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
1791-7530
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--administration & dosage
Breast Neoplasms--drug therapy
Cross-Sectional Studies
Female
Humans
Neoplasm Metastasis
Paclitaxel--administration & dosage
Quality of Life
Receptor, ErbB-2--metabolism
Triple Negative Breast Neoplasms--drug therapy